|
nasopharyngeal carcinoma |
165 |
|
humans |
128 |
|
female |
91 |
|
male |
84 |
|
radiotherapy |
83 |
|
middle aged |
77 |
|
adult |
76 |
|
aged |
71 |
|
cancer |
68 |
|
prognosis |
66 |
|
chemotherapy |
65 |
|
animals |
56 |
|
medical sciences |
50 |
|
survival |
50 |
|
cell line, tumor |
49 |
|
hepatocellular carcinoma |
48 |
|
neoplasm staging |
47 |
|
chinese |
46 |
|
immunotherapy |
43 |
|
oncology |
43 |
|
metastasis |
42 |
|
mice |
42 |
|
epstein-barr virus |
40 |
|
quality of life |
39 |
|
aged, 80 and over |
38 |
|
covid-19 |
38 |
|
biomarker |
37 |
|
chemoradiotherapy |
37 |
|
treatment outcome |
36 |
|
esophageal squamous cell carcinoma |
35 |
|
gene expression regulation, neoplastic |
35 |
|
targeted therapy |
35 |
|
lung cancer |
34 |
|
esophageal cancer |
33 |
|
hong kong |
33 |
|
nasopharyngeal cancer |
33 |
|
breast cancer |
32 |
|
dna methylation |
32 |
|
npc |
32 |
|
gene expression profiling |
31 |
|
surgery |
31 |
|
immunohistochemistry |
30 |
|
mice, nude |
30 |
|
reverse transcriptase polymerase chain reaction |
30 |
|
survival analysis |
30 |
|
disease-free survival |
29 |
|
follow-up studies |
29 |
|
randomized controlled trial |
29 |
|
tumor cells, cultured |
29 |
|
prognostic factors |
28 |
|
chromosome aberrations |
27 |
|
epidemiology |
27 |
|
non-small cell lung cancer |
27 |
|
apoptosis |
26 |
|
transfection |
26 |
|
cisplatin |
25 |
|
efficacy |
25 |
|
genes, tumor suppressor |
25 |
|
hcc |
25 |
|
in situ hybridization, fluorescence |
25 |
|
methylation |
25 |
|
neoplasm metastasis |
25 |
|
nucleic acid hybridization |
25 |
|
survival rate |
25 |
|
adolescent |
24 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
24 |
|
lymphatic metastasis |
24 |
|
tumor suppressor gene |
24 |
|
whole-exome sequencing |
24 |
|
combined modality therapy |
23 |
|
gene amplification |
23 |
|
loss of heterozygosity |
23 |
|
polymorphism, single nucleotide |
23 |
|
risk factors |
23 |
|
capecitabine |
22 |
|
colorectal cancer |
22 |
|
escc |
22 |
|
chemoresistance |
21 |
|
chi-square distribution |
21 |
|
gastric cancer |
21 |
|
intensity-modulated radiotherapy |
21 |
|
promoter regions, genetic |
21 |
|
promoter regions, genetic - genetics |
21 |
|
radiotherapy dosage |
21 |
|
retrospective studies |
21 |
|
safety |
21 |
|
transplantation, heterologous |
21 |
|
tumor microenvironment |
21 |
|
tumor suppressor |
21 |
|
cell cycle |
20 |
|
chemotherapy, adjuvant |
20 |
|
china |
20 |
|
disease progression |
20 |
|
gene expression |
20 |
|
mutation |
20 |
|
nasopharyngeal neoplasms - genetics |
20 |
|
neoplasm transplantation |
20 |
|
polymerase chain reaction |
20 |
|
head and neck cancer |
19 |
|
imrt |
19 |
|
nasopharyngeal carcinoma (npc) |
19 |
|
promoter hypermethylation |
19 |
|
signal transduction |
19 |
|
squamous cell carcinoma |
19 |
|
base sequence |
18 |
|
blotting, western |
18 |
|
cancer stem cells |
18 |
|
carcinoma |
18 |
|
immune checkpoint inhibitors |
18 |
|
incidence |
18 |
|
lymph nodes - pathology |
18 |
|
meta-analysis |
18 |
|
plasma ebv dna |
18 |
|
prognostication |
18 |
|
recurrence |
18 |
|
risk assessment |
18 |
|
treatment |
18 |
|
alleles |
17 |
|
carcinoma, squamous cell - genetics - metabolism - pathology |
17 |
|
cell proliferation |
17 |
|
ebv |
17 |
|
esophageal neoplasms - genetics - metabolism - pathology |
17 |
|
genomic instability |
17 |
|
induction chemotherapy |
17 |
|
late toxicity |
17 |
|
lymph node metastasis |
17 |
|
neoplasm invasiveness |
17 |
|
oligonucleotide array sequence analysis |
17 |
|
prospective studies |
17 |
|
staging |
17 |
|
asian continental ancestry group |
16 |
|
china - epidemiology |
16 |
|
drug resistance, neoplasm |
16 |
|
e-cadherin |
16 |
|
emt |
16 |
|
genetic predisposition to disease |
16 |
|
intensity-modulated radiation therapy |
16 |
|
liver cancer |
16 |
|
neoadjuvant therapy |
16 |
|
oesophageal squamous cell carcinoma |
16 |
|
prognostic marker |
16 |
|
reliability |
16 |
|
respiratory system - virology |
16 |
|
validity |
16 |
|
case-control studies |
15 |
|
cell differentiation |
15 |
|
chromosomes, human, pair 6 - genetics |
15 |
|
dce-mri |
15 |
|
epithelial-mesenchymal transition |
15 |
|
local recurrence |
15 |
|
magnetic resonance imaging |
15 |
|
molecular sequence data |
15 |
|
nomogram |
15 |
|
prognostic factor |
15 |
|
radiation |
15 |
|
radiomics |
15 |
|
young adult |
15 |
|
adc |
14 |
|
brachytherapy |
14 |
|
cancer survivors |
14 |
|
cells, cultured |
14 |
|
chromosome deletion |
14 |
|
chromosomes, human, pair 3 |
14 |
|
deep learning |
14 |
|
epigenetics |
14 |
|
epstein–barr virus |
14 |
|
esophageal carcinoma |
14 |
|
heterogeneity |
14 |
|
liquid biopsy |
14 |
|
mice, inbred balb c |
14 |
|
nasopharyngeal neoplasms - genetics - metabolism - pathology |
14 |
|
non-small-cell lung cancer |
14 |
|
palliative care |
14 |
|
radiotherapy, adjuvant |
14 |
|
reirradiation |
14 |
|
reproducibility of results |
14 |
|
systematic review |
14 |
|
time factors |
14 |
|
tissue microarray |
14 |
|
toxicity |
14 |
|
tumor-initiating cells |
14 |
|
angiogenesis |
13 |
|
cadherins - metabolism |
13 |
|
cancer susceptibility genes |
13 |
|
carcinoma, squamous cell - genetics |
13 |
|
cell line |
13 |
|
cell line, transformed |
13 |
|
chromosome mapping |
13 |
|
chromosomes, human, pair 3 - genetics |
13 |
|
chromosomes, human, pair 9 - genetics |
13 |
|
conjunctiva - virology |
13 |
|
down-regulation |
13 |
|
early-age onset |
13 |
|
glycoproteins - metabolism |
13 |
|
hong kong - epidemiology |
13 |
|
invasion |
13 |
|
mice, scid |
13 |
|
microrna |
13 |
|
mst1r |
13 |
|
overall survival |
13 |
|
pet/ct |
13 |
|
radiology and nuclear medicine |
13 |
|
smoking |
13 |
|
t-lymphocytes, cytotoxic - immunology |
13 |
|
tissue array analysis |
13 |
|
toxicities |
13 |
|
tumor suppression |
13 |
|
virulence |
13 |
|
adenocarcinoma |
12 |
|
antineoplastic agents - pharmacology |
12 |
|
apobec-mediated signature |
12 |
|
biopsy |
12 |
|
bronchi - cytology |
12 |
|
cancer stemness |
12 |
|
cd133 |
12 |
|
cell division |
12 |
|
cell movement |
12 |
|
chronic diseases |
12 |
|
comparative genomic hybridization |
12 |
|
dna damage |
12 |
|
esophageal squamous cell carcinoma (escc) |
12 |
|
gamma rays |
12 |
|
genes, tumor suppressor - physiology |
12 |
|
health services |
12 |
|
hypoxia |
12 |
|
influenza a virus, h1n1 subtype - metabolism |
12 |
|
influenza, human - virology |
12 |
|
liver neoplasms - metabolism - pathology |
12 |
|
microcell-mediated chromosome transfer |
12 |
|
mind-body intervention |
12 |
|
nasopharyngeal neoplasms - radiotherapy |
12 |
|
neoplasm recurrence, local |
12 |
|
nf-κb signaling |
12 |
|
non-communicable diseases |
12 |
|
phenotype |
12 |
|
precision oncology |
12 |
|
public health |
12 |
|
qigong |
12 |
|
radiation therapy |
12 |
|
responsiveness |
12 |
|
somatic mutation landscape |
12 |
|
stereotactic body radiation therapy |
12 |
|
survivorship |
12 |
|
treatment outcomes |
12 |
|
tumor stem cell assay |
12 |
|
tumor suppressor proteins - genetics - metabolism |
12 |
|
up-regulation |
12 |
|
xenograft model antitumor assays |
12 |
|
accelerated fractionation |
11 |
|
adult oncology |
11 |
|
analysis of variance |
11 |
|
apoptosis - drug effects |
11 |
|
cancer progression |
11 |
|
cell transformation, neoplastic |
11 |
|
child |
11 |
|
chromosomes, human, pair 14 - genetics |
11 |
|
computed tomography |
11 |
|
dose fractionation |
11 |
|
dose-response relationship, drug |
11 |
|
dose-response relationship, radiation |
11 |
|
epidermal growth factor receptor |
11 |
|
esophagectomy |
11 |
|
intravoxel incoherent motion |
11 |
|
karyotyping |
11 |
|
liver regeneration |
11 |
|
measurement invariance |
11 |
|
microsatellite repeats |
11 |
|
nasopharyngeal neoplasms - genetics - pathology |
11 |
|
nasopharyngectomy |
11 |
|
next-generation sequencing |
11 |
|
nidogen-2 (nid2) |
11 |
|
older adults |
11 |
|
phosphorylation |
11 |
|
proteomics |
11 |
|
stereotactic body radiotherapy |
11 |
|
transcription, genetic |
11 |
|
tyrosine kinase inhibitor |
11 |
|
xerostomia |
11 |
|
adam proteins - genetics |
10 |
|
adamts9 |
10 |
|
age factors |
10 |
|
antiangiogenesis |
10 |
|
antigens, cd - genetics - metabolism |
10 |
|
antigens, cd - metabolism |
10 |
|
arhgap fusions |
10 |
|
asian continental ancestry group - genetics |
10 |
|
assessment |
10 |
|
biobank |
10 |
|
carcinogenicity tests |
10 |
|
carcinoma - genetics |
10 |
|
case-control study |
10 |
|
cell movement - drug effects |
10 |
|
cell proliferation - drug effects |
10 |
|
chromosome segregation |
10 |
|
cognitive behavioral therapy |
10 |
|
cohort studies |
10 |
|
cross-sectional studies |
10 |
|
diagnosis |
10 |
|
dna-binding proteins - genetics - metabolism |
10 |
|
dnmt1 |
10 |
|
down-regulation - drug effects |
10 |
|
drug screening |
10 |
|
ebv genome |
10 |
|
enzyme activation |
10 |
|
epithelial cells - drug effects - pathology |
10 |
|
esophageal neoplasms - genetics |
10 |
|
extracellular matrix protein |
10 |
|
family caregiver |
10 |
|
frailty |
10 |
|
genetic markers |
10 |
|
in situ hybridization |
10 |
|
inflammation |
10 |
|
influenza a virus, h1n1 subtype - genetics - growth & development - pathogenicity |
10 |
|
influenza a virus, h1n2 subtype - genetics - growth & development - pathogenicity |
10 |
|
influenza a virus, h5n1 subtype - metabolism |
10 |
|
influenza, human - metabolism - transmission |
10 |
|
loh |
10 |
|
lung neoplasms - genetics |
10 |
|
metastatic colorectal cancer |
10 |
|
microcell hybrid |
10 |
|
molecular sequence numbers |
10 |
|
molecular tumour board |
10 |
|
nasopharyngeal neoplasms |
10 |
|
neoplasm invasiveness - pathology |
10 |
|
nf-κb |
10 |
|
nhej |
10 |
|
nsclc |
10 |
|
nucleic acid hybridization - methods |
10 |
|
oesophageal cancer |
10 |
|
organ culture techniques |
10 |
|
organoid culture |
10 |
|
peptides - metabolism |
10 |
|
radiation dose |
10 |
|
reassortant viruses - isolation & purification |
10 |
|
receptors, cell surface - metabolism |
10 |
|
recurrent |
10 |
|
respiratory mucosa - virology |
10 |
|
rhoa mutations |
10 |
|
salvage treatment |
10 |
|
screening |
10 |
|
sensitivity and specificity |
10 |
|
sequence-directed therapy |
10 |
|
sex factors |
10 |
|
spectrometry, mass, matrix-assisted laser desorption-ionization |
10 |
|
statistics, nonparametric |
10 |
|
survival prediction |
10 |
|
swine |
10 |
|
thy1 |
10 |
|
transarterial chemoembolization |
10 |
|
transcriptome sequencing |
10 |
|
viral tropism |
10 |
|
virus attachment |
10 |
|
xenograft |
10 |
|
25-hydroxyvitamin d |
9 |
|
adam proteins - biosynthesis - genetics - metabolism |
9 |
|
adverse events of special interest (aesi) |
9 |
|
allelic imbalance |
9 |
|
antineoplastic agents - therapeutic use |
9 |
|
arginine methylation |
9 |
|
biomarkers |
9 |
|
bnt162b2 |
9 |
|
breast neoplasms |
9 |
|
carcinoma, non-small-cell lung - enzymology - genetics - pathology |
9 |
|
carcinoma, squamous cell - epidemiology - genetics - pathology |
9 |
|
cell cycle arrest |
9 |
|
cell death - drug effects |
9 |
|
cell transformation, neoplastic - genetics |
9 |
|
checkpoint inhibitors |
9 |
|
chromatin accessibility |
9 |
|
chromosome 6p |
9 |
|
chromosomes, human, pair 11 |
9 |
|
chromosomes, human, pair 11 - genetics |
9 |
|
cognitive behavioural therapy |
9 |
|
concurrent chemoradiotherapy |
9 |
|
coronavac |
9 |
|
cytology and histology |
9 |
|
cytotoxicity |
9 |
|
dietary fiber |
9 |
|
dna |
9 |
|
dna - genetics |
9 |
|
drug resistance |
9 |
|
dual specificity phosphatase 6 - genetics - metabolism |
9 |
|
dual-specificity phosphatase 6 (dusp6) |
9 |
|
dw-mri |
9 |
|
electrophoresis, gel, two-dimensional |
9 |
|
endothelial cells - cytology |
9 |
|
esophageal neoplasms - blood supply - enzymology - genetics |
9 |
|
fact-c |
9 |
|
family caregivers |
9 |
|
flow cytometry |
9 |
|
fresh vegetable and fruit |
9 |
|
genetic epidemiology |
9 |
|
genetic susceptibility |
9 |
|
genetic variant |
9 |
|
genome-wide association study |
9 |
|
genotype |
9 |
|
herpesvirus 4, human - genetics |
9 |
|
host-virus interaction |
9 |
|
illumina humanmethylation450 |
9 |
|
immortalization |
9 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
9 |
|
leucocyte telomere length |
9 |
|
life-course |
9 |
|
liver neoplasms - genetics - metabolism - pathology |
9 |
|
lung neoplasms - enzymology - genetics - pathology |
9 |
|
metastatic |
9 |
|
methylome |
9 |
|
microsatellite repeats - genetics |
9 |
|
milk |
9 |
|
mipol1 |
9 |
|
mrs |
9 |
|
multiple imputation |
9 |
|
multivariate analysis |
9 |
|
nasopharyngeal neoplasms - blood supply - enzymology - genetics |
9 |
|
neoadjuvant chemoradiotherapy |
9 |
|
nf-kappa b - metabolism |
9 |
|
npc risk |
9 |
|
nuclear proteins - genetics - metabolism |
9 |
|
oncology medical sciences |
9 |
|
outcomes |
9 |
|
physical activity |
9 |
|
precision medicine |
9 |
|
preserved food |
9 |
|
rad51 recombinase |
9 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
9 |
|
recursive partitioning analysis |
9 |
|
rna, messenger - metabolism |
9 |
|
snp |
9 |
|
soybean product |
9 |
|
stage classification |
9 |
|
telomere biology |
9 |
|
tuberculosis reactivation |
9 |
|
tumor immune microenvironment |
9 |
|
tumor markers, biological - metabolism |
9 |
|
tumor suppressor proteins - genetics |
9 |
|
tumorigenesis |
9 |
|
ultraviolet radiation |
9 |
|
vaccine |
9 |
|
vitamin d |
9 |
|
vitamin d deficiency |
9 |
|
whole-genome bisulfite sequencing |
9 |
|
adaptor proteins, signal transducing - physiology |
8 |
|
adenocarcinoma - genetics |
8 |
|
aging, premature - genetics |
8 |
|
bintrafusp alfa |
8 |
|
bone marrow cells - physiology - radiation effects |
8 |
|
brca1 protein - genetics |
8 |
|
cancer chemotherapy |
8 |
|
carcinoma - genetics - pathology |
8 |
|
carcinoma - radiotherapy |
8 |
|
carcinoma, hepatocellular - genetics - metabolism |
8 |
|
carcinoma, hepatocellular - metabolism - pathology |
8 |
|
carcinoma, hepatocellular - metabolism - pathology - secondary |
8 |
|
carcinoma, squamous cell - genetics - pathology |
8 |
|
carrier proteins - metabolism |
8 |
|
cell aging - genetics |
8 |
|
cell survival - drug effects - physiology |
8 |
|
cervical cancer |
8 |
|
chemokine cxcl1 - physiology |
8 |
|
child, preschool |
8 |
|
chromosomal proteins, non-histone |
8 |
|
cigarette smoking |
8 |
|
circulating neoplastic cell |
8 |
|
circulating tumor cells |
8 |
|
circulating tumor dna |
8 |
|
complications |
8 |
|
concurrent chemotherapy |
8 |
|
correlative biomarkers |
8 |
|
cranial irradiation - adverse effects |
8 |
|
cyclin d1 - genetics - metabolism |
8 |
|
cytokines - genetics - physiology |
8 |
|
cytotoxic t cells |
8 |
|
dna damage - genetics |
8 |
|
dna repair - physiology |
8 |
|
dna, neoplasm - genetics |
8 |
|
dose-response relation |
8 |
|
dosimetric predictors |
8 |
|
early detection |
8 |
|
epigenetic regulation |
8 |
|
etv4 |
8 |
|
fibroblasts - pathology - radiation effects |
8 |
|
gastroenterology medical sciences |
8 |
|
genes, p53 |
8 |
|
genetics |
8 |
|
glycoproteins - deficiency - genetics - metabolism |
8 |
|
glycoproteins - genetics - metabolism |
8 |
|
head and neck cancers |
8 |
|
herpesvirus 4, human - immunology |
8 |
|
histones - genetics - metabolism - radiation effects |
8 |
|
hypothyroidism |
8 |
|
interleukin-8 - deficiency - genetics - physiology |
8 |
|
lamin type a - genetics - metabolism |
8 |
|
liver - metabolism - pathology - physiopathology |
8 |
|
liver neoplasms - genetics - metabolism |
8 |
|
lmp1 |
8 |
|
local control |
8 |
|
longitudinal real-time monitoring |
8 |
|
membrane proteins - genetics - metabolism |
8 |
|
metalloendopeptidases - genetics - metabolism |
8 |
|
mice, mutant strains |
8 |
|
microarray analysis |
8 |
|
mortality |
8 |
|
neoplasm proteins - metabolism |
8 |
|
neoplasm staging - methods |
8 |
|
neovascularization, pathologic - genetics |
8 |
|
non-invasive biomarker |
8 |
|
non-metastatic |
8 |
|
nrp2 |
8 |
|
oesophagectomy |
8 |
|
outcome |
8 |
|
ovarian cancer |
8 |
|
phosphoproteins - genetics - metabolism |
8 |
|
polymorphism, genetic - genetics |
8 |
|
positron emission tomography |
8 |
|
predictive value of tests |
8 |
|
prevalence |
8 |
|
protein precursors - genetics - metabolism |
8 |
|
radiation dosage |
8 |
|
recurrent or metastatic nasopharyngeal cancer |
8 |
|
rna interference |
8 |
|
rna‐seq |
8 |
|
saliva |
8 |
|
salivation - radiation effects |
8 |
|
second primary cancer |
8 |
|
sequence |
8 |
|
smoking cessation |
8 |
|
survival outcome |
8 |
|
telomerase |
8 |
|
telomere length |
8 |
|
transcription regulator |
8 |
|
tumor markers, biological |
8 |
|
tumor markers, biological - analysis |
8 |
|
tumor markers, biological - genetics - metabolism |
8 |
|
tumor suppressor proteins - metabolism |
8 |
|
tyrosine kinase inhibitors |
8 |
|
unresectable |
8 |
|
β-catenin |
8 |
|
-depression |
7 |
|
3p21 |
7 |
|
5-fluorouracil |
7 |
|
acupuncture |
7 |
|
advanced escc |
7 |
|
alpha b-crystallin (cryab) |
7 |
|
alpha-crystallin b chain - physiology |
7 |
|
anchor |
7 |
|
animal experiment |
7 |
|
animal model |
7 |
|
anti-angiogenic |
7 |
|
azygos vein blood |
7 |
|
blm |
7 |
|
breast neoplasms - epidemiology - genetics |
7 |
|
cancer incidence |
7 |
|
cancer-associated venous thrombosis (cat) |
7 |
|
cancer-related distress |
7 |
|
carcinoma, hepatocellular - drug therapy - physiopathology - secondary |
7 |
|
carcinoma, hepatocellular - metabolism |
7 |
|
carcinoma, non-small-cell lung - genetics |
7 |
|
carcinoma, squamous cell - genetics - pathology - secondary |
7 |
|
ccdc170 |
7 |
|
cd8+ t cells |
7 |
|
cell adhesion |
7 |
|
cell survival |
7 |
|
cell transformation, neoplastic - metabolism |
7 |
|
cell-free dna |
7 |
|
centromere |
7 |
|
centromere - drug effects - metabolism |
7 |
|
cetuximab |
7 |
|
chromatids - genetics - metabolism |
7 |
|
chromosomal instability - genetics |
7 |
|
chromosome 11q |
7 |
|
chromosomes, human - genetics |
7 |
|
chromosomes, human, pair 12 - genetics |
7 |
|
chromosomes, human, pair 17 |
7 |
|
circulating mirna |
7 |
|
circulating tumor cells (ctc) |
7 |
|
colorectal neoplasm |
7 |
|
controlled study |
7 |
|
cost-effectiveness |
7 |
|
cost-of-illness |
7 |
|
ctc clusters |
7 |
|
ctc enumeration |
7 |
|
cyclin b1 - genetics - metabolism |
7 |
|
defect |
7 |
|
delineation |
7 |
|
diagnosis and prognosis |
7 |
|
diffusion magnetic resonance imaging |
7 |
|
direct medical cost |
7 |
|
direct oral anticoagulants (doacs) |
7 |
|
distant metastases |
7 |
|
distress |
7 |
|
dna dsb repair |
7 |
|
dna primers |
7 |
|
dna probes |
7 |
|
early diagnosis |
7 |
|
early prediction |
7 |
|
egfr |
7 |
|
endothelial cells - drug effects |
7 |
|
enzyme-linked immunosorbent assay |
7 |
|
episome |
7 |
|
epithelial cells - metabolism - physiology |
7 |
|
epstein-barr virus infections - complications - genetics - metabolism - virology |
7 |
|
erk1/2 |
7 |
|
esophageal neoplasms - epidemiology - genetics - pathology |
7 |
|
extranodal extension |
7 |
|
familial npc |
7 |
|
fibulin-2 |
7 |
|
g 2 checkpoint |
7 |
|
g2 phase - genetics |
7 |
|
gene silencing |
7 |
|
genomic adjusted radiation dose |
7 |
|
graves’ disease |
7 |
|
hbv infection |
7 |
|
head and neck |
7 |
|
health care service provider |
7 |
|
health-related quality of life |
7 |
|
hepatitis b virus - genetics |
7 |
|
hepatitis b, chronic - genetics - immunology - metabolism |
7 |
|
herpesvirus 4, human - genetics - pathogenicity |
7 |
|
histone modifications |
7 |
|
histones - metabolism |
7 |
|
hypoxia-inducible factor 1, alpha subunit - metabolism |
7 |
|
id‐1 |
7 |
|
ifnar1 |
7 |
|
illness perception |
7 |
|
image processing, computer-assisted |
7 |
|
immunoglobulins - deficiency - genetics - physiology |
7 |
|
inhibitor of differentiation protein 1 - antagonists & inhibitors - genetics - metabolism |
7 |
|
insomnia |
7 |
|
instability |
7 |
|
irradiation microcell-mediated chromosome transfer |
7 |
|
liver neoplasms - drug therapy - physiopathology - secondary |
7 |
|
liver transplantation |
7 |
|
long-term cancer survivors |
7 |
|
low-molecular-weight heparin (lmwh) |
7 |
|
lymphatic metastasis - genetics |
7 |
|
lymphopenia |
7 |
|
markov state-transition model |
7 |
|
membrane proteins - deficiency - genetics - physiology |
7 |
|
microarray analysis - methods |
7 |
|
microrna therapy |
7 |
|
migration |
7 |
|
mir‐338‐5p |
7 |
|
mitochondria |
7 |
|
mitosis |
7 |
|
mmp19 |
7 |
|
multidisciplinary |
7 |
|
mutations |
7 |
|
nasopharyngeal neoplasms - drug therapy - genetics - metabolism |
7 |
|
nasopharynx - metabolism - pathology - virology |
7 |
|
neoplasm invasiveness - genetics |
7 |
|
neoplasms |
7 |
|
neovascularization, pathologic - metabolism |
7 |
|
network meta-analysis |
7 |
|
nuclear proteins - metabolism |
7 |
|
nucleosome organization |
7 |
|
occupation |
7 |
|
oligodeoxyribonucleotides, antisense - pharmacology - therapeutic use |
7 |
|
p21 |
7 |
|
p38 signaling |
7 |
|
p53 |
7 |
|
palliative |
7 |
|
parotid sparing |
7 |
|
pathway associations |
7 |
|
perfusion |
7 |
|
personalize |
7 |
|
pet imaging |
7 |
|
pharyngectomy |
7 |
|
pilot projects |
7 |
|
proteins - antagonists & inhibitors - genetics - metabolism |
7 |
|
quality-adjusted life years (qalys) |
7 |
|
questionnaires |
7 |
|
radiation injuries - complications |
7 |
|
radiosurgery |
7 |
|
randomised controlled trial |
7 |
|
rassf1a |
7 |
|
receptor, interferon alpha-beta - genetics |
7 |
|
reference values |
7 |
|
return to work |
7 |
|
rna sequencing |
7 |
|
sensorineural hearing loss |
7 |
|
service utilization |
7 |
|
sf-12 |
7 |
|
sleep disturbance |
7 |
|
sleep quality |
7 |
|
sleep trajectory |
7 |
|
spectral karyotyping |
7 |
|
stat5a |
7 |
|
statistics as topic |
7 |
|
structure-activity relationship |
7 |
|
survivor |
7 |
|
telomerase - metabolism |
7 |
|
telomere |
7 |
|
tert |
7 |
|
therapeutics |
7 |
|
thyroid cancer |
7 |
|
tomography, x-ray computed |
7 |
|
transcription regulation |
7 |
|
transcriptional activation - physiology |
7 |
|
tumor burden |
7 |
|
tumor marker |
7 |
|
tumor markers, biological - blood |
7 |
|
tumor markers, biological - genetics |
7 |
|
tumor-associated macrophage |
7 |
|
twist transcription factor - metabolism |
7 |
|
vaccination |
7 |
|
vascular endothelial growth factor a - genetics - metabolism - secretion |
7 |
|
vegf |
7 |
|
viral persistence |
7 |
|
whole‐exome sequencing |
7 |
|
work productivity |
7 |
|
znf750 mutation |
7 |
|
adaptive planning |
6 |
|
adaptor proteins, signal transducing - genetics - metabolism |
6 |
|
adherens junctions - metabolism |
6 |
|
adjuvant |
6 |
|
adverse events |
6 |
|
alpha b-crystallin |
6 |
|
amino acid sequence |
6 |
|
ampk |
6 |
|
androgen receptor |
6 |
|
animal tissue |
6 |
|
anti-angiogenesis |
6 |
|
antigens, differentiation - metabolism |
6 |
|
antigens, thy-1 - genetics - metabolism |
6 |
|
antigens, thy-1 - physiology |
6 |
|
antiinvasive |
6 |
|
apoptosis - genetics |
6 |
|
autoimmune disease |
6 |
|
bq323636.1 |
6 |
|
cancer immunosuppression |
6 |
|
cancer survivor |
6 |
|
cancer vaccine |
6 |
|
carcinoma - genetics - secondary |
6 |
|
carcinoma - metabolism - pathology |
6 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology |
6 |
|
carcinoma, squamous cell - metabolism - mortality |
6 |
|
carrier proteins - genetics |
6 |
|
cell separation |
6 |
|
cell signaling |
6 |
|
chemicals and cas registry numbers |
6 |
|
chromosome 11 |
6 |
|
chromosome 3, metastasis |
6 |
|
chromosomes, human, pair 1 - genetics |
6 |
|
chromosomes, human, pair 13 - genetics |
6 |
|
chromosomes, human, pair 8 |
6 |
|
confirmatory factor analysis |
6 |
|
conservation |
6 |
|
crip2 |
6 |
|
ctc |
6 |
|
cxcl8 |
6 |
|
cxcr2 |
6 |
|
cytokine |
6 |
|
decision-making |
6 |
|
deficit accumulation |
6 |
|
deoxycytidine - pharmacology |
6 |
|
dna damage repair pathway |
6 |
|
dna methylation - drug effects |
6 |
|
dna, neoplasm - analysis |
6 |
|
dna, viral - analysis |
6 |
|
dna, viral - isolation & purification |
6 |
|
dna-binding proteins - genetics |
6 |
|
dose escalation |
6 |
|
dosimetry |
6 |
|
double-negative b cells |
6 |
|
economic evaluation |
6 |
|
economic evidence |
6 |
|
epstein−barr virus |
6 |
|
esophageal neoplasms - metabolism - mortality |
6 |
|
fatal outcome |
6 |
|
fluorescent antibody technique |
6 |
|
follow up |
6 |
|
frailty phenotype |
6 |
|
gene deletion |
6 |
|
gene expression regulation, neoplastic - drug effects |
6 |
|
gene expression regulation, neoplastic - physiology |
6 |
|
genes, cdc - physiology |
6 |
|
genome, human - genetics |
6 |
|
global health |
6 |
|
half-life clearance |
6 |
|
health care |
6 |
|
hepatocellular carcinomas |
6 |
|
histone bivalent switch |
6 |
|
human |
6 |
|
human leukocyte antigen |
6 |
|
hydroxamic acids - pharmacology |
6 |
|
hypermethylation |
6 |
|
immunoenzyme techniques |
6 |
|
instant messaging |
6 |
|
invasiveness |
6 |
|
ivim |
6 |
|
latent tgf-beta binding proteins - genetics - metabolism |
6 |
|
latent transforming growth factor β binding protein 2 (ltbp-2) |
6 |
|
lim domain proteins - genetics - metabolism |
6 |
|
local clinical remission |
6 |
|
longitudinal studies |
6 |
|
ltbp-2 |
6 |
|
lung neoplasms |
6 |
|
m2 macrophages |
6 |
|
machine learning |
6 |
|
mastectomy, segmental |
6 |
|
matrix stiffness |
6 |
|
mechanoepigenetics |
6 |
|
medical records |
6 |
|
mental health |
6 |
|
metabolic reprogramming |
6 |
|
metastatic growth |
6 |
|
mhealth |
6 |
|
mif |
6 |
|
mlh1 |
6 |
|
mode of administration |
6 |
|
molecular genetics |
6 |
|
ms‐hrm |
6 |
|
mtor |
6 |
|
muscle development |
6 |
|
nasopharyngeal neoplasms - metabolism - pathology |
6 |
|
nasopharynx |
6 |
|
neovascularization, pathologic |
6 |
|
nidogen-2 |
6 |
|
npc genetics |
6 |
|
older cancer patients |
6 |
|
oligo-microarray |
6 |
|
oncogene |
6 |
|
oral health |
6 |
|
oxaliplatin |
6 |
|
oxidative stress |
6 |
|
palbociclib |
6 |
|
palliative chemotherapy |
6 |
|
pancreatic neoplasms |
6 |
|
patient-derived xenografts |
6 |
|
pattern of failure |
6 |
|
pediatric |
6 |
|
pericardial effusion |
6 |
|
pi3k/akt |
6 |
|
plasma |
6 |
|
plasma epstein–barr virus deoxyribonucleic acid |
6 |
|
plasmids |
6 |
|
post-treatment plasma ebv dna |
6 |
|
postradiation malignancies |
6 |
|
prognostic predictor |
6 |
|
prostate cancer |
6 |
|
radiogenomic |
6 |
|
radiotherapy, intensity-modulated |
6 |
|
receptor-like protein tyrosine phosphatases, class 5 - genetics - physiology |
6 |
|
rhabdomyosarcoma |
6 |
|
saha |
6 |
|
salivary flow |
6 |
|
salvage therapy |
6 |
|
sbrt |
6 |
|
serum biomarker |
6 |
|
silibinin |
6 |
|
simulation models |
6 |
|
staging system |
6 |
|
stem cells - metabolism - pathology |
6 |
|
stomach neoplasms |
6 |
|
sulforaphane |
6 |
|
suv |
6 |
|
tamoxifen resistance |
6 |
|
tetracycline-regulated gene expression |
6 |
|
thbs2 |
6 |
|
thrombospondins - genetics - metabolism |
6 |
|
tnm staging |
6 |
|
tomography, x-ray computed - methods |
6 |
|
traditional chinese medicine |
6 |
|
translocation, genetic |
6 |
|
tumor cell dormancy |
6 |
|
tumor metastasis |
6 |
|
tumor staging |
6 |
|
tumor suppressor genes |
6 |
|
tumor suppressor protein p53 - biosynthesis - genetics |
6 |
|
tumour spheres |
6 |
|
twist1 |
6 |
|
wif1 |
6 |
|
2-methoxyestradiol |
5 |
|
3' untranslated region |
5 |
|
[11c]-acetate |
5 |
|
acupressure |
5 |
|
adenocarcinoma - drug therapy - economics |
5 |
|
adenoviridae - immunology |
5 |
|
adjuvant therapy |
5 |
|
aetiology |
5 |
|
aggressiveness |
5 |
|
aldehyde dehydrogenase - metabolism |
5 |
|
algorithms |
5 |
|
antibodies, monoclonal - diagnostic use |
5 |
|
antigen expression |
5 |
|
antigens, cd - biosynthesis - physiology |
5 |
|
antineoplastic agents |
5 |
|
antineoplastic agents, phytogenic - pharmacology |
5 |
|
antineoplastic combined chemotherapy protocols - administration and dosage - economics - therapeutic use |
5 |
|
antioncogenes. |
5 |
|
biopsy, needle |
5 |
|
blotting, southern |
5 |
|
bmi-1 |
5 |
|
brain metastasis |
5 |
|
brca2 |
5 |
|
canagliflozin |
5 |
|
cancer inhibition |
5 |
|
cancer outcomes |
5 |
|
cancer site-standardized relative survival |
5 |
|
cancer stem cell |
5 |
|
cancer survival |
5 |
|
candidiasis, oral - classification |
5 |
|
carcinoma - blood - diagnosis - genetics |
5 |
|
carcinoma, hepatocellular - genetics - pathology |
5 |
|
carcinoma, non-small-cell lung - genetics - pathology |
5 |
|
carcinoma, squamous cell |
5 |
|
carcinoma, squamous cell - ethnology - metabolism - pathology |
5 |
|
carcinoma, squamous cell - genetics - metabolism |
5 |
|
carcinoma, squamous cell - mortality - pathology - therapy |
5 |
|
carrier proteins - genetics - physiology |
5 |
|
cell death |
5 |
|
cell division - drug effects |
5 |
|
cell survival - drug effects |
5 |
|
cgh |
5 |
|
chemobrain |
5 |
|
chemotherapy-induced peripheral neuropathy |
5 |
|
cheung chau island |
5 |
|
childhood lymphoma |
5 |
|
chromosome 3 |
5 |
|
chromosomes, human, pair 10 - genetics |
5 |
|
chromosomes, human, pair 20 |
5 |
|
chromosomes, human, pair 3 - ultrastructure |
5 |
|
chromosomes, human, pair 5 - genetics |
5 |
|
cisplatin - pharmacology |
5 |
|
clone cells |
5 |
|
cluster analysis |
5 |
|
colorectal neoplasms - drug therapy - economics |
5 |
|
combination therapy |
5 |
|
ct |
5 |
|
cyclin d1 |
5 |
|
cyclin e |
5 |
|
cytokines - blood - genetics - metabolism |
5 |
|
dapagliflozin |
5 |
|
dental caries |
5 |
|
dental caries - classification |
5 |
|
dental professionals |
5 |
|
dental students |
5 |
|
diagnosis, differential |
5 |
|
diet |
5 |
|
differentiation |
5 |
|
diffusion weighted imaging |
5 |
|
diffusion-weighted imaging |
5 |
|
dmf index |
5 |
|
dna - metabolism |
5 |
|
dna mutational analysis |
5 |
|
dna, complementary - genetics |
5 |
|
dna, viral - blood |
5 |
|
dna-binding proteins - metabolism |
5 |
|
docetaxel |
5 |
|
drug repurposing |
5 |
|
drug resistance, neoplasm - physiology |
5 |
|
ductal carcinoma in situ |
5 |
|
ebv‐encoded small rna |
5 |
|
elderly |
5 |
|
endoreduplication |
5 |
|
enox2 |
5 |
|
epithelial cells - cytology |
5 |
|
epstein-barr virus infections - immunology - therapy |
5 |
|
epstein-barr virus nuclear antigens - immunology |
5 |
|
epstein–barr virus infection |
5 |
|
eq-5d-5 l |
5 |
|
ercc1 |
5 |
|
esophageal cancer surgery |
5 |
|
esophageal cancer susceptibility gene |
5 |
|
esophageal neoplasms - ethnology - metabolism - pathology |
5 |
|
esophageal neoplasms - genetics - metabolism |
5 |
|
esophageal neoplasms - mortality - pathology - therapy |
5 |
|
exosomes |
5 |
|
fascin |
5 |
|
fluorescence in situ hybridization |
5 |
|
folinic acid |
5 |
|
functional assessment |
5 |
|
galectin 9 |
5 |
|
gastroenterology |
5 |
|
gefitinib |
5 |
|
gene dosage |
5 |
|
gene expression regulation, neoplastic - genetics |
5 |
|
genome‐wide analysis |
5 |
|
gist |
5 |
|
glycoproteins - biosynthesis - physiology |
5 |
|
grp78 |
5 |
|
guideline |
5 |
|
health care costs - statistics and numerical data |
5 |
|
health economics |
5 |
|
health status indicators |
5 |
|
her2+ breast cancer |
5 |
|
her2-targeted therapy |
5 |
|
hospital authority |
5 |
|
hpv |
5 |
|
human papillomavirus |
5 |
|
hybrid cells |
5 |
|
icg-001 |
5 |
|
idronoxil |
5 |
|
igra |
5 |
|
illness perceptions |
5 |
|
immune checkpoint inhibitor |
5 |
|
immune regulation |
5 |
|
immunization, passive |
5 |
|
income |
5 |
|
infant |
5 |